BioDelivery Sciences International, Inc. BDSI Cash Flow

Biodelivery sciences international, inc. (BDSI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities:
Net loss
-6,506	-15,305	-21,617	-28,351	-26,991	-33,867	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (loss) income
-	-	-	-	-	-	-	-	-	-	5,553	1,527	-80	-67,138	-41,024	-45,487	-48,212	-37,672	-65,490	-70,306	-57,767	-54,218	-49,341	-42,572	-49,315	-57,394	-36,028	-35,018	-17,821	1,652	-11,027	1,325	-7,555	-23,325	0	0	0
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	281	406	459	466	575	536	490	444	0	0	0
Depreciation
-	-	-	-	-	-	-	-	0	-	-	-	462	437	406	374	330	329	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of debt discount and loan costs
10,939	11,508	12,626	13,730	4,147	4,138	3,404	2,683	1,977	2,392	2,041	1,690	1,338	397	397	420	437	500	560	599	643	642	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of intangible assets
7,492	7,000	6,416	5,809	5,200	5,200	5,165	5,243	5,320	5,400	4,346	3,221	2,097	971	970	970	971	970	972	972	971	972	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Provision for inventory obsolescence
453	197	-395	-319	159	-56	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative loss (gain)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,009	-10,242	-5,728	121	3,776	1,169	-2,701	-5,594	-8,439	-2,442	2,083	3,463	0	0	0
Stock-based compensation expense
5,795	5,416	5,023	4,648	4,161	5,941	9,474	12,805	14,652	14,801	13,554	13,474	13,890	14,931	13,146	14,048	14,853	14,249	14,729	12,062	9,243	6,883	5,696	4,440	3,889	3,327	3,017	2,284	1,741	1,619	1,308	1,478	1,442	1,226	0	0	0
Deferred income taxes
-	-	-	-	-	-	-	-	-	-15,972	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bargain purchase gain
-	-	-	-	-	-	-	-	-	27,336	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Arcion license with common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,072	0	0	0	-	-	-	-	-	-	-	-
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable
29,106	25,163	20,854	15,469	7,885	4,640	2,243	3,849	2,358	5,884	7,483	3,400	3,880	862	1,665	864	-917	-670	1,202	-11,113	500	347	-680	12,130	2,304	2,273	861	486	30	420	-1,628	-197	-542	-530	0	0	0
Inventories
8,196	6,102	4,936	3,486	1,977	-741	-395	680	-2,684	-2,448	-2,964	-3,697	-1,933	810	2,131	2,893	2,271	730	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-370	581	719	1,142	142	-422	1,845	-946	-1,114	-526	-2,160	-510	127	203	1,175	1,177	1,424	1,365	2,174	2,149	2,002	2,252	741	16	-113	68	130	118	-94	-4	-21	-713	194	-6	0	0	0
Accounts payable and accrued liabilities
37,381	32,275	12,464	7,389	2,420	-2,807	-2,781	2,347	-711	6,644	8,114	2,074	2,834	-1,546	3,916	6,824	4,490	5,055	1,824	2,717	5,707	4,325	2,022	-2,379	-611	-656	3,540	5,938	4,274	5,568	362	367	-1,563	407	0	0	0
Taxes payable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-21,922	-21,965	-21,640	-159	14,686	14,718	14,526	14,262	746	1,504	2,972	3,405	1,085	-1,434	-4,944	-6,500	-21,571	-21,674	-18,563	-3,446	12,814	14,669	13,394	7	0	0	0
Net cash flows used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-46,328	-53,982	-12,374	-12,953	-15,383	-3,732	-50,751	-39,445	-34,449	-28,833	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash flows used in operating activities
20,345	11,072	-11,687	-16,742	-20,238	-24,113	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	15,299	22,621	5,364	-23,274	0	0	0
Investing activities:
Product acquisitions
-	-	-	-	-	1,951	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisitions of equipment
0	79	36	69	118	112	0	0	0	-	-	-	-	405	398	367	793	701	668	1,166	905	1,603	0	0	0	-	-	-	-	39	104	184	310	286	0	0	0
Purchase of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,050	0	0	0	-	-	-	-
Net cash flows used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-405	-398	-367	-793	-701	-668	-1,166	-905	-1,603	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash flows used in investing activities
-30,685	-30,764	-20,710	-20,743	-118	-2,063	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,154	-1,234	-1,360	-286	0	0	0
Financing activities:
Equity financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sales of securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
2,187	2,321	1,335	1,434	1,012	670	0	0	0	-	-	-	-	297	572	677	849	755	487	2,050	2,151	4,580	0	0	0	-	-	-	-	-	-	-	-	349	0	0	0
Proceeds from issuance of common stock, less underwriters discount
-	-	-	-	-	-	-	-	-	-	-	-	-	2,460	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,996	0	0	0
Proceeds from exercise of common stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,741	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment on note payable
-	-	-	-	-	-	-	-	-	30,000	0	0	0	-	-	-	-	3,335	5,335	6,668	7,334	7,333	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	60,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Return of short swing profits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	6	6	6	82	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of deferred financing fees
-	-	-	-	-	450	600	600	600	2,948	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash flows (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	12,323	2,846	3,025	3,129	22,110	17,521	20,054	29,902	10,614	77,732	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in amounts due to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Change in amounts due to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net cash flows provided by financing activities
39,624	39,758	38,778	38,976	49,595	48,803	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,054	455	1,889	16,103	0	0	0
Net change in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
-	-	-	-	-	-	-	0	-23,129	-	-24,936	-29,956	-34,174	-51,541	-9,747	-10,191	5,934	13,088	-31,365	-10,709	-24,740	47,296	47,498	40,933	38,532	-40,013	6,976	-5,599	17,551	52,439	16,199	21,842	5,893	-7,458	0	0	0
Cash paid for interest
6,320	6,809	6,747	6,635	6,104	6,053	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	3,137	2,870	2,729	2,752	2,295	1,885	1,522	1,053	1,223	1,386	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of bargain purchase price of BELBUCA acquisition
-	-	-	-	-	-	-	-	-	27,300	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-